BSG and head and neck squamous cell carcinoma: Using a neutralizing antibody to uPAR could down-regulate the HNSCC resistance to cisplatin induced by CD147 over-expression, resulting in increased HNSCC sensitivity to cisplatin, which may indicate that CD147 and uPAR collaborate in the chemoresistance process [148].